+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Natco Pharma Ltd (NATCOPHARM) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 56 Pages
  • November 2022
  • GlobalData
  • ID: 1323072
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Natco Pharma Ltd (NATCOPHARM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Natco Pharma Ltd (Natco Pharma) focuses on the discovery, development, manufacturing, and commercialization of pharmaceutical substances and finished dosage forms. The company offers finished dosages in capsule, injection and tablet forms. Its products are indicated to treat multiple sclerosis, influenza infection, multiple myeloma, leukemia, Crohn's disease, hypertension, myelodysplastic syndrome, prostate cancer and others. Natco Pharma offers active pharmaceutical ingredients (APIs) in the domestic and international markets. It operates API and finished dosage facilities and a research center in India. The company operates in India, the US, Canada, and Europe. Natco Pharma is headquartered in Hyderabad, Telangana, India.

Natco Pharma Ltd Key Recent Developments

  • May 24, 2022: Edelweiss Securities Invitation to Natco Pharma Q4 FY22 Earnings call
  • May 23, 2022: NATCO Pharma announces legal update
  • Nov 11, 2021: Natco Pharma announces Unaudited Financial Results Standalone and Consolidated for the quarter and half year ended 30th September, 2021
  • Aug 12, 2021: NATCO records INR 427.30 crore consolidated revenue and INR 75 crore of profit, after tax, for the first quarter ended 30th June 2021

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Natco Pharma Ltd - Key Facts
  • Natco Pharma Ltd - Key Employees
  • Natco Pharma Ltd - Key Employee Biographies
  • Natco Pharma Ltd - Major Products and Services
  • Natco Pharma Ltd - History
  • Natco Pharma Ltd - Company Statement
  • Natco Pharma Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Natco Pharma Ltd - Business Description
  • Business Segment: Active Pharmaceutical Ingredients
  • Overview
  • Performance
  • Key Stats
  • Business Segment: Crop Health Sciences
  • Overview
  • Performance
  • Key Stats
  • Business Segment: Domestic Formulations
  • Overview
  • Performance
  • Key Stats
  • Business Segment: International Formulations
  • Overview
  • Performance
  • Key Stats
  • Business Segment: Other Operating and Non-Operating Incomes
  • Performance
  • Geographical Segment: India
  • Performance
  • Geographical Segment: Rest of the world
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • Natco Pharma Ltd - Corporate Strategy
  • Natco Pharma Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Natco Pharma Ltd - Strengths
  • Natco Pharma Ltd - Weaknesses
  • Natco Pharma Ltd - Opportunities
  • Natco Pharma Ltd - Threats
  • Natco Pharma Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Natco Pharma Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 24, 2022: Edelweiss Securities Invitation to Natco Pharma Q4 FY22 Earnings call
  • May 23, 2022: NATCO Pharma announces legal update
  • Nov 11, 2021: Natco Pharma announces Unaudited Financial Results Standalone and Consolidated for the quarter and half year ended 30th September, 2021
  • Aug 12, 2021: NATCO records INR 427.30 crore consolidated revenue and INR 75 crore of profit, after tax, for the first quarter ended 30th June 2021
  • Aug 09, 2021: Natco Pharma Announces Q1 FY22 Earnings call
  • Jul 07, 2021: NATCO: Legal Update
  • Jun 17, 2021: NATCO records INR 2155.7 crore consolidated revenue and INR 442.4 crore of profit, after tax, for the full year ended March 2021
  • Jun 17, 2021: Natco Pharma Announces Statement of Standalone financial results for the quarter and year ended March 31, 2021
  • May 28, 2021: Zydus Cadila files for DCGI approval to study Covid-19 drug in India
  • May 17, 2021: Natco Pharma and Lilly sign licencing deal for baricitinib use in India
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Natco Pharma Ltd, Key Facts
  • Natco Pharma Ltd, Key Employees
  • Natco Pharma Ltd, Key Employee Biographies
  • Natco Pharma Ltd, Major Products and Services
  • Natco Pharma Ltd, History
  • Natco Pharma Ltd, Other Locations
  • Natco Pharma Ltd, Subsidiaries
  • Natco Pharma Ltd, Joint Venture
  • Natco Pharma Ltd, Key Competitors
  • Natco Pharma Ltd, Ratios based on current share price
  • Natco Pharma Ltd, Annual Ratios
  • Natco Pharma Ltd, Interim Ratios
  • Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Natco Pharma Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Natco Pharma Ltd, Performance Chart (2018 - 2022)
  • Natco Pharma Ltd, Ratio Charts
  • Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Samples

Loading
LOADING...

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Medicamen Biotech Ltd
  • Piramal Enterprises Ltd
  • Jubilant Pharmova Ltd
  • Biocon Ltd
  • Suven Life Sciences Ltd
  • Divi's Laboratories Ltd
  • Suven Life Sciences Ltd
  • Divi's Laboratories Ltd
  • Biocon Ltd
  • Piramal Enterprises Ltd
  • Medicamen Biotech Ltd
  • Jubilant Pharmova Ltd